“Growing Shift to Automated and Multiplex Platforms”
- One prominent trend in the global immunoassay reagents and devices market is the growing shift to automated and multiplex platforms
- This trend is driven by the rising demand for high-throughput, accurate, and efficient diagnostic solutions, especially in managing large testing volumes in hospitals and laboratories
- For instance, companies such as Roche and Abbott are introducing advanced immunoassay systems with automation and multiplexing capabilities, allowing simultaneous detection of multiple biomarkers with minimal hands-on time
- The increasing focus on streamlining lab workflows and reducing turnaround times is also driving the adoption of these next-gen platforms
- As healthcare systems prioritize precision diagnostics and operational efficiency, the shift to automated and multiplex immunoassay platforms is expected to play a key role in market growth
